Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome
Portfolio Pulse from Benzinga Newsdesk
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) announced that a new International Classification of Diseases, Tenth Revision (ICD-10) diagnosis code for Bardet-Biedl Syndrome (BBS) was approved by the Centers for Disease Control and Prevention (CDC). The new code, Q87.83 Bardet-Biedl syndrome (BBS), takes effect Oct. 1, 2023.
September 06, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rhythm Pharmaceuticals' new ICD-10 diagnosis code for Bardet-Biedl Syndrome could potentially increase the recognition and diagnosis of the disease, potentially leading to increased use of their treatments.
The new ICD-10 code for Bardet-Biedl Syndrome could lead to increased recognition and diagnosis of the disease. This could potentially increase the demand for Rhythm Pharmaceuticals' treatments for the disease, positively impacting their stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100